Jupiter Neurosciences, Inc. (JUNS)
NASDAQ: JUNS · Real-Time Price · USD
1.140
-0.080 (-6.56%)
At close: Dec 5, 2025, 4:00 PM EST
1.120
-0.020 (-1.75%)
After-hours: Dec 5, 2025, 7:40 PM EST
Jupiter Neurosciences Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Net Income | -7.6 | -2.44 | -4.78 | -4.96 | -4.2 | -1.65 | |
| Other Amortization | 0.66 | 0.1 | 0.02 | 0.56 | 0.08 | - | |
| Stock-Based Compensation | 2.97 | 1.84 | 1.2 | 0.82 | 1.43 | 0.56 | |
| Other Operating Activities | 0.09 | -0.84 | 0.74 | 0.78 | 0.18 | -0.13 | |
| Change in Accounts Receivable | - | - | - | - | 0.13 | -0.13 | |
| Change in Accounts Payable | -0.19 | -0.15 | 0.16 | -0.06 | -0.16 | 0.19 | |
| Change in Other Net Operating Assets | -2.68 | -2.42 | 2.18 | 1.61 | 0.81 | 0.9 | |
| Operating Cash Flow | -6.74 | -3.91 | -0.48 | -1.25 | -1.74 | -0.25 | |
| Short-Term Debt Issued | - | 0.14 | 0.39 | 0.98 | 0.53 | 0.02 | |
| Total Debt Issued | 0 | 0.14 | 0.39 | 0.98 | 0.53 | 0.02 | |
| Short-Term Debt Repaid | - | -2.36 | - | - | - | -0.25 | |
| Total Debt Repaid | -2.36 | -2.36 | - | - | - | -0.25 | |
| Net Debt Issued (Repaid) | -2.36 | -2.22 | 0.39 | 0.98 | 0.53 | -0.24 | |
| Issuance of Common Stock | 0.1 | 0.15 | 0.06 | - | 1.33 | 0.7 | |
| Other Financing Activities | 9.73 | 9.73 | - | - | - | - | |
| Financing Cash Flow | 7.47 | 7.65 | 0.45 | 0.98 | 1.86 | 0.46 | |
| Net Cash Flow | 0.72 | 3.74 | -0.04 | -0.27 | 0.12 | 0.21 | |
| Cash Interest Paid | 0.09 | 0.15 | 0.03 | 0.08 | 0 | - | |
| Levered Free Cash Flow | -3.16 | -2.92 | -3.12 | -0.83 | 0.25 | -0.6 | |
| Unlevered Free Cash Flow | -3.17 | -2.81 | -3 | -0.92 | 0.24 | -0.59 | |
| Change in Working Capital | -2.86 | -2.57 | 2.35 | 1.55 | 0.78 | 0.96 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.